You are here

FDA Announces Recall of Valsartan-containing Products

An impurity has been found to be carcinogenic.

An impurity called N-nitrosodimethylamine (NDMA) was found in several of products containing valsartan, which is used to treat heart failure and high blood pressure. But not all products containing valsartan are being recalled. And the FDA said that because valsartan is used to treat serious medical condition, patients should keep on taking the recalled products until they have a replacement.

Based on some laboratory tests, researchers have determined that NDMA could cause cancer. “The presence of NDMA was unexpected and is thought to be related to changes in the way the active substance was manufactured,” the FDA said in a press release.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time